3SBio of Shenyang received CFDA approval to begin China trials of its in-licensed product PEG-irinotecan, a long-acting chemotherapy. The drug is a polymer-drug conjugate that inhibits topoisomerase I, which is over-expressed in many solid tumors. 3SBio intends to develop PEG-irinotecan as a China Class I drug for relapsed or refractory cancers, including colorectal, metastatic breast and platinum-resistant ovarian cancers. 3SBio in-licensed the drug from China’s JenKem Technology in 2014.
